AppLovin Stock Before Q2 Earnings: To Buy or Not to Buy?
The Zacks Consensus Estimate for earnings in the to-be-reported quarter stands at $1.99, indicating 123.6% growth from the year-ago reported quarter. The consensus estimate for revenues stands at $1.21 billion, implying 12.3% year-over-year growth.
Two estimates for the second quarter were revised upward in the past 30 days, against no upward revision. The Zacks Consensus Estimate has declined 1.5% during this time frame.
The company has a strong history of earnings surprises. Earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, with an earnings surprise of 22.9%, on average.
Q2 Earnings Beat likely for APP
Our proven model predicts a likely earnings beat for APP this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
APP has an Earnings ESP of +2.59% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here.
Advertising Should Drive Performance Growth
We expect year-over-year improvement in the company's top line in the to-be-reported quarter to be driven mainly by Advertising. The consensus estimate for the Advertising revenues is pegged at $1.23 billion, indicating 72% year-over-year growth. The consensus mark for the Advertising's adjusted EBITDA is pegged at $1 billion, suggesting 92% year-over-year growth.
APP Stock is in a Great Mood
APP has rallied a staggering 465% over the past year, easily outpacing the broader industry 's 71% growth. Competitors like Alphabet GOOGL and Meta Platforms META have also delivered strong results. Alphabet shares gained 19% during the same time frame, while Meta Platforms climbed 58%. Both Alphabet and Meta Platforms remain major players, but AppLovin's specialized platform is delivering superior returns in this niche.
Investment Risk and Rewards for APP
AppLovin has solidified its leadership in mobile advertising, powered by its next-gen AI engine, Axon 2, which launched in the second quarter of 2023. Since its debut, Axon 2 has radically enhanced AppLovin's ad performance, helping to quadruple advertising spend on its platform.
AppLovin's financial performance has matched its technological breakthroughs. In the first quarter of 2025, revenues surged 40% year over year, reflecting strong market demand. Adjusted EBITDA jumped 83% year over year, showcasing improved operational efficiency. Net income skyrocketed 144% from the prior year, demonstrating APP's ability to translate revenue growth into significant profitability. For the full year 2024, revenues climbed 43% year over year, while adjusted EBITDA surged 81%, underscoring AppLovin's ability to seize market opportunities while maintaining efficiency.
Cautious Optimism Ahead of Earnings
AppLovin has shown exceptional momentum, driven by strong advertising performance and the continued success of its AI engine, Axon 2. The company's track record of surpassing earnings expectations adds confidence ahead of its upcoming report. However, recent estimate revisions suggest mixed sentiment, and the stock's sharp rally may already reflect much of the optimism. With expectations running high and peers performing well, it's wise to stay cautious. A hold strategy is recommended for now. Let the earnings results validate the stock's next move before considering any fresh positions. Patience could be rewarding at this stage.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
AppLovin Corporation (APP): Free Stock Analysis Report
Alphabet Inc. (GOOGL): Free Stock Analysis Report
Meta Platforms, Inc. (META): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
2 minutes ago
- CBC
Ontario-made alcohol gets largest tax cut in decades
Ontario's new alcohol tax cut, which is intended to support local producers, took effect last week. The province says the move will make the industry more competitive amid U.S. tariffs and growing economic pressures.
Globe and Mail
3 minutes ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CTV News
an hour ago
- CTV News
Scott Moe speaks out against AI ‘deepfakes' of him circulating online
Saskatchewan Premier Scott Moe listens to a question from the media during the 2025 summer meetings of Canada's Premiers at Deerhurst Resort in Huntsville, Ont., on Wednesday, July 23, 2025. THE CANADIAN PRESS/Nathan Denette Saskatchewan Premier Scott Moe says his government is doing whatever it can to track down the creators of so-called 'deepfakes' of him and other prominent figures. Moe's likeness, including his voice, has been used in online video ads for cryptocurrency schemes that he says he would never endorse. The premier says on his official social media that some of the videos, which are created with artificial intelligence, feature him and others, including Prime Minister Mark Carney. Moe says his government is doing its best to find the people behind the videos, but adds it can be difficult to prevent the scams. It's not the first time Moe's image has been used to market the scams — he first acknowledged them in March. Saskatchewan's consumer watchdog has been issuing warnings about the impersonation scams and urges people not to send money to companies that aren't registered in the province. This report by The Canadian Press was first published Aug. 4, 2025.
